Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite

Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology

Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

Biotium introduces novel antibody labeling Kits for efficient labeling of IgM antibodies

Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Venus Remedies receives approval to market meropenm in Spain

The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries

Max Healthcare and IIT Bombay ink MoU for innovation in the healthcare industry

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine

The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield